SCHEMBL23832811

SCHEMBL23832811

O=S(=O)(Nc1ccc(Cl)c(Cl)c1)N1CCOC(C(c2ccc(F)cc2)c2ccc(F)cc2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
FKBP1A P62942 2/20 0.40
KMT2A Q03164 2/20 0.40
GLA P06280 1/20 0.40
CCR2 P41597 1/20 0.38
KCNH2 Q12809 1/20 0.38
EPHA2 P29317 1/20 0.38
KDR P35968 1/20 0.38
EPHB4 P54760 1/20 0.38
SLC6A3 Q01959 5/20 0.36
MGAT2 Q10469 1/20 0.36
MOGAT2 Q3SYC2 1/20 0.36
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
HSD17B3 P37058 1/20 0.34
HSD17B2 P37059 1/20 0.34
KIT P10721 1/20 0.34
MTOR P42345 1/20 0.34
RICTOR Q6R327 1/20 0.34
MAPKAP1 Q9BPZ7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23848610 0.89 KMT2A (0.50) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL23832805 0.89 KMT2A (0.45) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL25168299 0.89 FKBP1A (0.43) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL23832785 0.88 KMT2A (0.42) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL23848476 0.84 KMT2A (0.45) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL25501797 0.84 KMT2A (0.44) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL25501803 0.83 MAPT (0.41) POLBKMT2AMGAT2MOGAT2MAPT
SCHEMBL25502088 0.83 KMT2A (0.40) FKBP1AKMT2AGLAMGAT2MOGAT2
SCHEMBL25502166 0.83 FKBP1A (0.42) POLBFKBP1AKMT2AGLAMGAT2
SCHEMBL23848606 0.82 KMT2A (0.43) POLBFKBP1AKMT2AGLAMGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382270-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2025-12-18 US disclosed
US-12398103-B2 3-diarylmethylenes and uses thereof ATUX ISKAY LLC (US) 2025-08-26 US disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 US disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 US disclosed
EP-4121031-A1 3-DIARYLMETHYLENES AND USES THEREOF Atux Iskay LLC (US) 2023-01-25 EP disclosed
WO-2021188949-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382270-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 POLB 1988/4885FKBP1A 1315/4885KMT2A 742/4885
US-12398103-B2 3-diarylmethylenes and uses thereof MYC, MYCBP, FOXO1 POLB 1988/4885FKBP1A 1315/4885KMT2A 742/4885
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 POLB 1988/4885FKBP1A 1315/4885KMT2A 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.